Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie för att utvärdera den långsiktiga säkerheten och effekten av en subkutan formulering av Efgartigimod hos vuxna med aktiv idiopatisk inflammatorisk myopati (ALKIVIA+)

15 oktober 2026 uppdaterad av: argenx

En fas 3, enarmad, multicenter, öppen förlängning av studien ARGX-113-2007 för att undersöka den långsiktiga säkerheten, tolerabiliteten och effekten av Efgartigimod PH20 SC hos deltagare 18 år och äldre med aktiv idiopatisk inflammatorisk myopati

The main purpose of this study is to measure the long-term safety and tolerability of efgartigimod PH20 SC in adult participants with Idiopathic Inflammatory Myopathy (IIM) who previously participated in ARGX-113-2007.

The study consists of a treatment period where participants will receive efgartigimod PH20 SC for up to 51 months. The treatment period will be followed by a treatment-free safety follow-up period of 56 days.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

240

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • La Plata, Argentina, B1902COS
        • Framingham Centro Medico
      • San Miguel, Argentina, B1663GKT
        • Centro Dermatologico Schejtman
      • San Miguel de Tucumán, Argentina, 4000
        • Centro Medico Privado de Reumatologia
      • Ghent, Belgien, 9000
        • AZ Sint-Lucas - Campus Sint-Lucas - Neurology
      • Leuven, Belgien, 3000
        • Universitair Ziekenhuis Leuven Gasthuisberg Campus
      • Plovdiv, Bulgarien, 4002
        • Multiprofile hospital for active treatment Kaspela EOOD
      • Plovdiv, Bulgarien, 4002
        • Medical Centre Artmed
      • Nicosia, Cypern, 2371
        • Cyprus Institute of Neurology and Genetics
      • Copenhagen, Danmark, 2100
        • Copenhagen University Hospital-Rigshospitalet University Hospital
      • Paris, Frankrike, 75013
        • Reference Center Neuro-Muscular Diseases - CHU Paris Group Hospitalier La Pitie Salpetriere-Charles Foix
    • Arizona
      • Phoenix, Arizona, Förenta staterna, 85028
        • Neuromuscular Clinical and Research Center - Neurology
    • California
      • Beverly Hills, California, Förenta staterna, 90039
        • Attune Health Research, Inc
      • Orange, California, Förenta staterna, 92868
        • UCI Health - ALS and Neuromuscular Center - Neurology
      • San Francisco, California, Förenta staterna, 94143
        • UCSF Health - ALS and Neurodegenerative Disease Center - Dermatology
    • Connecticut
      • New Haven, Connecticut, Förenta staterna, 06520
        • Yale Cancer Center-Yale University School Of Medicine
    • Florida
      • Gainesville, Florida, Förenta staterna, 32610
        • UF Health - Rheumatology Medical Specialties Medical Plaza
      • Jacksonville, Florida, Förenta staterna, 32224
        • Mayo Clinic - Florida - Neurology
      • Tampa, Florida, Förenta staterna, 33616
        • University of South Florida (USF) - Morsani Center (USF Health Carol and Frank Morsani Center for Advanced Healthcare)
    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30322
        • Emory Healthcare - Emory Clinic - Rheumatology
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60611
        • Northwestern Medicine - Northwestern Memorial Hospital
    • Maryland
      • Baltimore, Maryland, Förenta staterna, 21224-2734
        • John Hopkins Medicine - Johns Hopkins Myositis Center
    • New York
      • Great Neck, New York, Förenta staterna, 11021
        • Northwell Health Physician Partners Rheumatology
    • North Carolina
      • Chapel Hill, North Carolina, Förenta staterna, 27514
        • University of North Carolina (UNC) School of Medicine
    • Ohio
      • Columbus, Ohio, Förenta staterna, 43201
        • The Ohio State University
    • Oregon
      • Portland, Oregon, Förenta staterna, 97239
        • Oregon Health and Science University
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Förenta staterna, 15261
        • University of Pittsburgh Medical Center
    • Texas
      • Austin, Texas, Förenta staterna, 78759
        • Austin Neuromuscular Center (National Neuromuscular Research Institute, PLLC)
      • Houston, Texas, Förenta staterna, 77030
        • Nerve And Muscle Center Of Texas
      • Tbilisi, Georgien, 0160
        • Aversi Clinic
      • Tbilisi, Georgien, 0180
        • The First Medical Center
      • Tbilisi, Georgien, 0160
        • LLC MediClub Georgia
      • Tbilisi, Georgien, 0162
        • New Hospitals
      • Athens, Grekland, 115 27
        • National and Kapodistrian University of Athens - School of Health Sciences - Faculty of Medicine
      • Athens, Grekland, 115 28
        • National and Kapodistrian University of Athens - Eginition Hospital
      • Athens, Grekland, 12462
        • ATTIKON University General Hospital - Neurology
      • Dublin, Irland, D04 T6F4
        • University College Dublin (UCD) - St. Vincent's University Hospital (SVUH)
      • Bari, Italien, 70124
        • Azienda Ospedaliero Universitaria Consorziale Policlinico
      • Milan, Italien, 20132
        • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele Hospital
      • Pisa, Italien, 56126
        • Azienda Ospedaliero Universitaria Pisana - Ospedale Santa Chiara - Rheumatology
      • Roma, Italien, 00189
        • Ospedale Sant'Andrea Hospital
      • Roma, Italien, 168
        • Fondazione Policlinico Universitario Agostino Gemelli - Neurology
      • Rozzano, Italien, 20089
        • IRCCS Istituto Clinico Humanitas
      • Udine, Italien, 33100
        • Azienda sanitaria universitaria Friuli Centrale - ASUFC
      • Bunkyō City, Japan, 113-8431
        • Juntendo University Hospital
      • Bunkyō City, Japan, 113-8655
        • The University of Tokyo Hospital
      • Nagoya, Japan, 457-8510
        • Japan Community Healthcare Organization Chukyo Hospital
      • Tokyo, Japan, 113-8519
        • Institute of Science Tokyo Hospital
      • Wakayama, Japan, 641-8510
        • Wakayama Medical University Hospital
      • Yamaguchi, Japan, 755-8505
        • Yamaguchi University Hospital
      • Beijing, Kina, 100730
        • Peking Union Medical College Hospital
      • Beijing, Kina, 100191
        • Peking University Third Hospital
      • Chengdu, Kina, 610072
        • Sichuan Provincial Academy of Medical Sciences and Sichuan Provincial People's Hospital
      • Shanghai, Kina, 200040
        • Huashan Hospital Affiliated to Fudan University
      • Shanghai, Kina, 200001
        • Shanghai Jiao Tong University School of Medicine - Renji Hospital - Shanghai Institute of Digestive Disease (SIDD)
      • Shenyang, Kina, 110001
        • China Medical University (CMU) - First Affiliated Hospital
      • Zhengzhou, Kina, 450052
        • First Affiliated Hospital (Henan Medical University - First Affiliated Hospital)-Zhengzhou University
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510515
        • Nanfang Hospital, Southern Medical University
    • Jingsu
      • Nanjing, Jingsu, Kina, 210000
        • Nanjing University Medical School - Taikang Xianlin Drum Tower Hospital (Nanjing Drum Tower Hospital)
      • Vilnius, Litauen, 08410
        • Santaros University Clinic
      • Mexico City, Mexiko, 06700
        • Hospital Angeles Clinica Londres
      • Amsterdam, Nederländerna, 1105 AZ
        • Amsterdam UMC Research BV
      • Arequipa, Peru, 4000
        • Clinica San Juan de Dios - sede Arequipa - Rheumatology
      • Lima, Peru, 33
        • Investigaciones Clinicas S.A.C.
      • Lima, Peru, 27
        • Instituto Peruano Del Hueso Y La Articulacion Sac-Privado-Lima,Centro De Investigacion Iphar
      • Lodz, Polen, 90-549
        • USK-WAM Centralny Szpital Weteranow - Szpital Kniniczny ul. Zeromskiego 113 - Rheumatology
      • Szczecin, Polen, 71-252
        • Centrum Wsparcia Badan Klinicznych Pomorskiego Uniwersytetu Medycznego w Szczecinie (CWBK PUM) - Rheumatology
      • Porto, Portugal, 4099-001
        • Centro Hospitalar do Porto - Hospital Santo Antonio
      • Belgrade, Serbien, 11000
        • Clinical Center of Serbia
      • Belgrade, Serbien, 11000
        • Institute of Rheumatology
      • Barcelona, Spanien, 08041
        • Hospital de la Santa Creu i Sant Pau
      • Madrid, Spanien, 28041
        • Hospital Universitario 12 de Octubre
      • Valencia, Spanien, 46026
        • Hospital Universitari i Politecnic La Fe de Valencia - Neurology
      • Liverpool, Storbritannien, L9 7AL
        • Aintree University Hospital - Liverpool University Hospitals NHS Foundation Trust
      • London, Storbritannien, NW3 2QG
        • The Royal Free Hospital
      • Salford, Storbritannien, M6 8HD
        • Northern Care Allicance NHS Foundation Trust - Salford Royal - Rheumatology
      • Solna, Sverige, 17176
        • Karolinska Universitestssjukhus Solna
      • Seoul, Sydkorea, 03080
        • Seoul National University Hospital
      • Taichung, Taiwan, 402
        • Chung Shan Medical University Hospital
      • Taichung, Taiwan
        • Taichung Veterans General Hospital
      • Bangkok, Thailand, 10400
        • Phramongkutklao Hospital
      • Bangkok, Thailand, 10330
        • King Chulalongkorn Memorial Hospital - Neurology
      • Bangkok, Thailand, 10700
        • Siriraj Hospital, Mahidol University of Internal medicine
      • Bangkok, Thailand, 10400
        • Ramathibodi hospital
      • Khon Kaen, Thailand, 40002
        • Faculty Of Medicine, Khon Kaen University
      • Prague, Tjeckien, 12850
        • Revmatologicky Ustav
      • Berlin, Tyskland, 10117
        • Charite Universitaetsmedizin Berlin - Campus Charite Mitte (CCM) - Rheumatology
      • Hamburg, Tyskland, 20246
        • Universitaetsklinikum Hamburg-Eppendorf
      • Herne, Tyskland, 44649
        • Rheumazentrum Ruhrgebiet
      • Mannheim, Tyskland, 68167
        • Universitatsmedizin Mannheim GmbH
      • Tübingen, Tyskland, 72076
        • Universitaetsklinikum Tuebingen (UKT)
      • Ulm, Tyskland, 89081
        • Klinikum der Universitaet Ulm
      • Innsbruck, Österrike, 6020
        • Tirol Kliniken - A.o. Landeskrankenhaus Innsbruck - Neurology

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Has completed trial ARGX-113-2007
  • Being capable of providing signed informed consent and complying with protocol requirements
  • Agrees to use contraceptive measures consistent with local regulations and women of childbearing potential must have a negative urine pregnancy test at baseline before receiving the study drug

Exclusion Criteria:

  • Intention to have major surgery during the study period or any other medical condition that has arisen since enrollment in study ARGX-113-2007, that in the investigator's opinion, would confound the results of the study or put the participant at undue risk
  • Known hypersensitivity reaction to the study drug or 1 of its excipients
  • Development of any malignancy, either new or recurrent, other than basal cell carcinoma of the skin, regardless of relatedness

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Efgartigimod PH20 SC

Participants receiving efgartigimod PH20 subcutaneously

Subcutaneous injection of Efgartigimod PH20 given by vials or prefilled syringe (PFS)

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of AEs, SAEs and AESIs over time
Tidsram: Up to 53 months

AE : adverse event ; SAE : serious adverse event ; AESI : adverse event of special interest.

Up to 53 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Prednisondosreduktion (genomsnittlig månadsdos) över tid
Tidsram: Upp till 51 månader
Upp till 51 månader
Procentuell förändring från baslinjen i totala IgG-nivåer i serum över tid
Tidsram: Upp till 53 månader
Upp till 53 månader
Doseringens varaktighet varannan vecka
Tidsram: Upp till 51 månader
Upp till 51 månader
C-GTI comprising the AIS over time
Tidsram: Up to 51 months

The Composite Glucocorticoid Toxicity Index (C-GTI) serves as a primary instrument to capture toxicities likely caused by glucocorticoid exposure and enables monitoring of long-term tolerability of glucocorticoids during prolonged use. The Aggregate Improvement Score (AIS) is an analytical scores generated from the weighted C-GTI. The AIS can be used to assess whether a new therapy is effective in reducing glucocorticoid toxicity over time; higher AIS scores are associated with less toxicity.

Up to 51 months
C-GTI comprising the CWS over time
Tidsram: Up to 51 months

The Composite Glucocorticoid Toxicity Index (C-GTI) serves as a primary instrument to capture toxicities likely caused by glucocorticoid exposure and enables monitoring of long-term tolerability of glucocorticoids during prolonged use. The Cumulative Worsening Score (CWS) is an analytical score generated from the weighted C-GTI. The CWS is designed to assess cumulative glucocorticoid toxicity; higher scores indicate increased steroid toxicity.

Up to 51 months
C-GTI comprising the GTI-MD over time
Tidsram: Up to 51 months

The Composite Glucocorticoid Toxicity Index (C-GTI) serves as a primary instrument to capture toxicities likely caused by glucocorticoid exposure and enables monitoring of long-term tolerability of glucocorticoids during prolonged use. The Glucocorticoid Toxicity Index-Metabolic Domains (GTI-MD) is an abbreviated GTI version limited to the 4 metabolic domains. A GTI-MD score of 0 indicates a low likelihood of toxicity in the assessed metabolic domains.

Up to 51 months
TIS over time
Tidsram: Up to 51 months

The total improvement score (TIS) assesses minimal, moderate, and major clinical response, and it is assessed using the ACR/EULAR criteria. The total score varies between 0 and 100, with higher scores indicating greater improvement.

Up to 51 months
Proportion of TIS responders (minimal, moderate, major) over time
Tidsram: Up to 51 months

The total improvement score (TIS) assesses minimal, moderate, and major clinical response, and it is assessed using the ACR/EULAR criteria. The total score varies between 0 and 100, with higher scores indicating greater improvement

Up to 51 months
Individual CSMs of the TIS over time
Tidsram: Up to 51 months

The total improvement score (TIS) assesses minimal, moderate, and major clinical response, and it is assessed using the ACR/EULAR criteria. The ACR/EULAR criteria calculate TIS using the 6 core set measure (CSMs): MDGA, PGA, MMT8, HAQ-DI, muscle enzymes, and extramuscular global assessment (assessed by the MDAAT).

Up to 51 months
Percentage of participants with clinically inactive disease
Tidsram: Up to 51 months

Clinically inactive disease is defined as no evidence of disease activity, based on an Physician Global Assessment of Disease Activity (MDGA) and Extramuscular Global Assessment of the Myositis Disease Activity Assessment Tool (MDAAT) of 0 and normal creatine kinase (CK) values for at least 12 weeks (at week 28 and every 24 weeks thereafter).

Up to 51 months
Percentage of participants with remission during the study
Tidsram: Up to 51 months

Remission is defined as a clinically inactive disease for at least 24 weeks

Up to 51 months
PGI-S over time
Tidsram: Up to 51 months

The Patient Global Impression of Severity (PGI-S) asks participants to rate the severity of their disease symptoms over the past 7 days on a 4-point Likert scale, where scores range from "no symptoms" to "severe."

Up to 51 months
CGI-S over time
Tidsram: Up to 51 months

The Clinical Global Impression of Severity (CGI-S) asks the physician to rate the severity of the participant's disease on a 4-point Likert scale, where scores range from "no activity" to "severe".

Up to 51 months
Physical Functioning subscale and Physical Component Summary scores of the SF-36v2 over time
Tidsram: Up to 51 months

The 36-Item Short Form Survey version 2 (SF-36v2) is a 36-item scale constructed to survey health-related quality of life in 8 domains.

Up to 51 months
EQ-5D-5L utilities over time
Tidsram: Up to 51 months

The EQ-5D-5L questionnaire is a standardized test recognized by many health authorities as a generic measure of health status for clinical and economic appraisal. The descriptive system comprises 5 dimensions, each having 5 levels ranging from "No problem" to "Extreme problem".

Up to 51 months
EQ-5D-5L VAS over time
Tidsram: Up to 51 months

The EQ-5D-5L questionnaire is a standardized test recognized by many health authorities as a generic measure of health status for clinical and economic appraisal. A visual analog scale (VAS) is included in the EQ-5D-5L, where participants will mark their health status from 0 (the worst health you can imagine) to 100 (the best health you can imagine).

Up to 51 months
Incidence of ADA against efgartigimod (serum levels) over time
Tidsram: Up to 53 months

ADA : anti-drug antibodies.

Up to 53 months
Proportion of participants achieving sustained low disease activity while on IMP, over time
Tidsram: Up to 51 months

Sustained low disease activity is defined as a CGI-S score of "mild" or "no activity" and a PGI-S score of "mild" or "no symptoms" for at least 12 weeks.

Up to 51 months
Proportion of participants with low disease activity over time, while on IMP
Tidsram: Up to 51 months

Low disease activity is defined as a CGI-S score of "mild" or "no activity" and a PGI-S score of "mild" or "no symptoms"

Up to 51 months
Proportion of participants with low disease activity who continue dosing every 2 weeks at week 52 and every 24 weeks thereafter
Tidsram: Up to 51 months

Low disease activity is defined as a CGI-S score of "mild" or "no activity" and a PGI-S score of "mild" or "no symptoms"

Up to 51 months
Proportion of participants who have marked worsening during the period of dosing every 2 weeks
Tidsram: Up to 51 months

Marked worsening is defined as a CGI-S score of "moderate" or "severe" and a PGI-S score of "moderate" or "severe"

Up to 51 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

12 september 2023

Primärt slutförande (Beräknad)

1 september 2028

Avslutad studie (Beräknad)

1 september 2028

Studieregistreringsdatum

Först inskickad

28 juli 2023

Först inskickad som uppfyllde QC-kriterierna

28 juli 2023

Första postat (Faktisk)

7 augusti 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

15 oktober 2026

Senast verifierad

1 juli 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera